City page
Oulu biotech and pharma directory
This page shows why the city matters, which categories are strongest there, and which compliance or quality markers are already visible in public evidence.
Where does this city read strongest?
CDMO (2) and CRO (1). Most visible records: Pharmatory, Paras Biopharmaceuticals Finland, and Admescope.
Which standards and public evidence are already visible?
GMP (1). Latest review: 22 March 2026. Review cycle: March 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Oulu.
By category
Oulu by category
Jump into a category page filtered to this country only.
Full list
Oulu biotech and pharma directory
3 city records currently match the active filter.
Current review cycle
Pharmatory
OuluFinlandCDMO
Oulu API CDMO providing process R&D, analytical services, and cGMP contract manufacturing for human and veterinary pharmaceutical clients.
- Lead
- Jaana KarjalainenCEO and Managing Director
- Scale
- Commercial and development-stage API platform
Current review cycle
Paras Biopharmaceuticals Finland
OuluFinlandCDMO
Oulu biopharmaceutical company focused on biosimilars, recombinant biologics, and process technologies from a Finnish operating base.
- Lead
- Ashesh KumarFounder and Director
- Scale
- Development-stage biologics platform
Current review cycle
Admescope
OuluFinlandCRO
Oulu CRO providing ADME-Tox, DMPK, bioanalysis, and drug-discovery support services for preclinical and translational development programs.
- Lead
- Outi KontkanenCEO
- Scale
- Commercial CRO service platform
Related briefs
Briefs that mention Oulu
Nordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway
A practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefEuropean Antibody & Biosimilar Therapeutics 2026: mAbs, ADCs, Biosimilars
A practical map of the European antibody + antibody-drug-conjugate + biosimilar therapeutics sector in 2026 — Genmab, ADC Therapeutics, Adcendo, Affimed, Tubulis, Heidelberg Pharma, Sandoz, Mabion, plus a Swedish + Swiss + Polish antibody innovator belt.
Open briefEuropean Drug Discovery Services 2026: CRO, Medicinal Chemistry, ADMET, DMPK
Where to run European drug discovery services in 2026 — Evotec, Selvita, Charles River Finland, Gubra, Admescope, plus a Swiss + Polish + Nordic tool + platform layer for medicinal chemistry, DMPK, ADMET, and translational research.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.